Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160004 | 0.84 | RAB9A (0.49) | LMNAGAAPKMKMT2ASMN1; SMN2 | |
| SCHEMBL21160014 | 0.83 | GAA (0.63) | LMNAGAAPKMKMT2ASMN1; SMN2 | |
| SCHEMBL21159803 | 0.78 | GAA (0.49) | LMNAGAAFASNPKMKMT2A | |
| SCHEMBL21085093 | 0.78 | GAA (0.49) | LMNAGAAFASNPKMKMT2A | |
| SCHEMBL19924471 | 0.78 | LMNA (0.68) | LMNAGAAPKMKMT2ASMN1; SMN2 | |
| SCHEMBL19957523 | 0.71 | KMT2A (0.60) | LMNAGAAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL12305501 | 0.71 | KMT2A (0.52) | LMNAGAAKMT2ASMN1; SMN2MEN1 | |
| Bicarbonate SCHEMBL7615814 | 0.68 | KMT2A (0.69) | LMNAFASNKMT2AMEN1EPHX2 | |
| SCHEMBL22382010 | 0.67 | GAA (0.73) | LMNAGAAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL21159809 | 0.67 | GAA (0.73) | LMNAGAAKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | LMNA 4657/4885GAA 101/4885FASN 3446/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | LMNA 4517/4885GAA 58/4885FASN 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.